ŠIMARA, Pavel, Lenka TESAŘOVÁ, Daniela ŘEHÁKOVÁ, Šimon FARKAŠ, Barbara ŠALINGOVÁ, Kateřina KUTÁLKOVÁ, Eva VAVREČKOVÁ, Pavel MATULA, Petr MATULA, Lenka VEVERKOVÁ and Irena KRONTORÁD KOUTNÁ. Reprogramming of Adult Peripheral Blood Cells into Human Induced Pluripotent Stem Cells as a Safe and Accessible Source of Endothelial Cells. Stem Cells and Development. Mary Ann Liebert, Inc. publishers, vol. 27, No 1, p. 10-22. ISSN 1547-3287. doi:10.1089/scd.2017.0132. 2018.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Reprogramming of Adult Peripheral Blood Cells into Human Induced Pluripotent Stem Cells as a Safe and Accessible Source of Endothelial Cells.
Authors ŠIMARA, Pavel (203 Czech Republic, belonging to the institution), Lenka TESAŘOVÁ (203 Czech Republic, belonging to the institution), Daniela ŘEHÁKOVÁ (203 Czech Republic, belonging to the institution), Šimon FARKAŠ (703 Slovakia, belonging to the institution), Barbara ŠALINGOVÁ (703 Slovakia, belonging to the institution), Kateřina KUTÁLKOVÁ (203 Czech Republic, belonging to the institution), Eva VAVREČKOVÁ (203 Czech Republic, belonging to the institution), Pavel MATULA (203 Czech Republic, belonging to the institution), Petr MATULA (203 Czech Republic, belonging to the institution), Lenka VEVERKOVÁ (203 Czech Republic) and Irena KRONTORÁD KOUTNÁ (203 Czech Republic, guarantor, belonging to the institution).
Edition Stem Cells and Development, Mary Ann Liebert, Inc. publishers, 2018, 1547-3287.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 10601 Cell biology
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 3.147
RIV identification code RIV/00216224:14330/18:00100772
Organization unit Faculty of Informatics
Doi http://dx.doi.org/10.1089/scd.2017.0132
UT WoS 000417686200001
Keywords in English induced pluripotent stem cells; endothelial differentiation; peripheral blood mononuclear cells
Tags cbia-web
Tags International impact, Reviewed
Changed by Changed by: RNDr. Pavel Šmerk, Ph.D., učo 3880. Changed: 29/4/2019 16:10.
Abstract
New approaches in regenerative medicine and vasculogenesis have generated a demand for sufficient numbers of human endothelial cells (ECs). ECs and their progenitors reside on the interior surface of blood and lymphatic vessels or circulate in peripheral blood; however, their numbers are limited, and they are difficult to expand after isolation. Recent advances in human induced pluripotent stem cell (hiPSC) research have opened possible avenues to generate unlimited numbers of ECs from easily accessible cell sources, such as the peripheral blood. In this study, we reprogrammed peripheral blood mononuclear cells, human umbilical vein endothelial cells (HUVECs), and human saphenous vein endothelial cells (HSVECs) into hiPSCs and differentiated them into ECs. The phenotype profiles, functionality, and genome stability of all hiPSC-derived ECs were assessed and compared with HUVECs and HSVECs. hiPSC-derived ECs resembled their natural EC counterparts, as shown by the expression of the endothelial surface markers CD31 and CD144 and the results of the functional analysis. Higher expression of endothelial progenitor markers CD34 and kinase insert domain receptor (KDR) was measured in hiPSC-derived ECs. An analysis of phosphorylated histone H2AX (gamma-H2AX) foci revealed that an increased number of DNA double-strand breaks upon reprogramming into pluripotent cells. However, differentiation into ECs restored a normal number of gamma-H2AX foci. Our hiPSCs retained a normal karyotype, with the exception of the HSVEC-derived hiPSC line, which displayed mosaicism due to a gain of chromosome 1. Peripheral blood from adult donors is a suitable source for the unlimited production of patient-specific ECs through the hiPSC interstage. hiPSC-derived ECs are fully functional and comparable to natural ECs. The protocol is eligible for clinical applications in regenerative medicine, if the genomic stability of the pluripotent cell stage is closely monitored.
Links
GBP302/12/G157, research and development projectName: Dynamika a organizace chromosomů během buněčného cyklu a při diferenciaci v normě a patologii
Investor: Czech Science Foundation
NV16-31501A, research and development projectName: Tkáňové inženýrství epitelů: Buňky a protokoly pro regenerativní medicínu
PrintDisplayed: 18/4/2024 02:26